| Previous Section | Index | Home Page |
26 Nov 2008 : Column 2100W—continued
The PTB is allocated direct to primary care trusts (PCTs) rather than being routed through the National Treatment Agency for Substance Misuse (NTA). The NTA's role is to ensure that allocations reflect local need, to monitor how funding is spent and to work with PCTs and Drug Action Teams to ensure that local treatment systems continue to improve and deliver effective and efficient services.
Neurofibromatosis
Sarah Teather: To ask the Secretary of State for Health what treatments for patients with neurofibromatosis are available; and if he will make a statement. [239351]
Ann Keen: Many people with neurofibromatosis are mildly affected only and are able to live a normal, healthy life. However, it is important that any complications are monitored by the appropriate specialists, so that action can be taken if they start to cause problems. Tumours that cause pain or discomfort can sometimes be surgically removed. If this is not possible because of the location or size of the tumour, pain-reducing medication may be prescribed by health professionals.
Neurology: Drugs
Daniel Kawczynski: To ask the Secretary of State for Health what proportion of the NHS’s budget was spent on medicine for the treatment of neurological illnesses in the latest period for which figures are available. [238364]
Ann Keen: Expenditure estimates relating to ‘Neurological System Problems’ are collected as part of the annual programme budgeting returns. The latest figures from the 2006-07 financial year suggest that 3.6 per cent. of national health service expenditure was accounted for by ‘Neurological System Problems’.
Neurology: Research
Daniel Kawczynski: To ask the Secretary of State for Health how much funding the Government have provided for research into neurological illnesses in the last 10 years. [238089]
Dawn Primarolo: The available information is shown in the following table:
| Neurological conditions research | ||
| £ million | ||
| Department | Medical Research Council( 1) | |
| (1) Neurosciences and mental health board portfolio. (2 )Not available. (3 )Chronic neurological disease only. (4) Not yet available. | ||
Over the last 10 years, the main part of the Department's total expenditure on health research has been devolved to and managed by national health service organisations. Those organisations have since 2001 accounted for their use of the research and development allocations received from the Department in an annual report. The information given in the table is derived from those reports and relates to expenditure on projects concerned with chronic neurological disease and degenerative neurological disorders.
NHS
Mr. Lansley: To ask the Secretary of State for Health what guidance his Department has issued to the NHS on bringing forward proposed capital projects. [238703]
Mr. Bradshaw: The Government announced in their pre-Budget report published on 24 November that they would bring forward £100 million of capital spending to financial years 2008-09 and 2009-10 to advance the upgrading of up to 600 GP surgeries to training practices. We intend to discuss further with the NHS and professional groups how best to deploy this investment.
Mr. Lansley: To ask the Secretary of State for Health what data his Department collects on serious untoward incidents in the NHS. [238898]
Ann Keen: Data relating to serious untoward incidents are not routinely collected by the Department. The National Patient Safety Agency collects and collates information related to serious patient safety incidents and deaths (as a result of patient safety incidents) which are reported to it from local national health service organisations through the National Reporting and Learning System.
NHS Information Centre
Mr. Lansley: To ask the Secretary of State for Health what information is recorded in the Hospital Pharmacy Audit Index to which the NHS information centre has access. [238906]
Dawn Primarolo: The NHS Information Centre for health and social care has access to the Health Hospital Pharmacy Audit Index (HPAI) database, which is supplied by IMS Health (Intercontinental Medical Statistics).
Data are collected from pharmacies in participating hospital trusts across the United Kingdom on a commercial basis and the section of the HPAI database relating to England has been made available by IMS on a monthly basis, subject to a contract between IMS Health and The Information Centre. The Information Centre receives data from this system at the level of the 28 strategic health authorities which existed prior to July 2006.
The HPAI is based on issues of medicines recorded on hospital pharmacy systems; the data record the volume of packs issued rather than the number of issuing events. This volume information is priced using the Drug Tariff and other price lists. ‘Issues’ refer to all medicines supplied from hospital pharmacies: to wards, departments, clinics, theatres, satellite sites and to patients in out-patient clinics and on discharge. Therefore, the HPAI monitors usage levels by hospitals rather than purchases by trusts which may be acting for a consortium of trusts.
NHS Purchasing and Supply Agency: Consultants
David Taylor: To ask the Secretary of State for Health how much the NHS Purchasing and Supply Agency spent on private sector consultancy fees in each of the last three financial years. [238418]
Mr. Bradshaw: The NHS Purchasing and Supply Agency spent the following on private sector consultancy in the last three financial years.
| £ | |
NHS Treatment Centres: York
Hugh Bayley: To ask the Secretary of State for Health how many patients have been treated at York NHS walk-in centre in each year since it opened. [236884]
Mr. Bradshaw: This information is not collected centrally. This information can be obtained from the North Yorkshire and York primary care trust directly.
NHS: Discharges
Joan Walley: To ask the Secretary of State for Health what financial penalties Stoke-on-Trent City Council has incurred in the last period for which figures are available as a result of delayed discharges from hospitals. [239506]
Phil Hope: The information is not collected centrally.
Joan Walley: To ask the Secretary of State for Health how many delayed discharges there were in (a) the West Midlands Strategic Health Authority area, (b) the Stoke-on-Trent Primary Care Trust area, (c) the North Staffordshire Primary Care Trust area and (d) England in each of the last five years, broken down by reason for delay; and how many patients in each case were occupying an acute hospital bed. [239509]
Phil Hope: The information requested is shown in the following tables.
| Acute delayed transfers of care and number of occupied acute beds, West Midlands strategic health authority (SHA), 2003-04 to 2007-08 | |||||
| Reason for delay | 2003-04 | 2004-05 | 2005-06 | 2006-07 | 2007-08 |
| Notes: 1. The aforementioned are shown for Shropshire and Staffordshire SHA, Birmingham and the Black Country SHA and West Midlands South SHA. These three SHAs merged to form West Midlands SHA on 1 July 2006. 2. Number of delayed transfers of care are collected as a snapshot at midnight Thursday each week. 3. The number of acute beds were only collected on a voluntary basis in the Weekly Situation Reports, from 18 December 2006. Therefore, annual data from the KH03 form have been shown for 2006-07 and 2007-08 instead. 4. The delayed transfers of care data shown is for adults (aged 18+). 5. Non-acute delayed of care data are available for 2007-08. However, the parliamentary question seems to request information for acute delayed transfers of care only. Source: Department of Health forms: Weekly Situation Reports and KH03 | |||||
| Next Section | Index | Home Page |